The FDA has granted orphan drug designation to Gotistobart for use in squamous non-small cell lung cancer. This designation is among recent developments in oncology, with other key drugs also receiving FDA designations. The potential of Gotistobart and other treatments, including a monoclonal antibody, is being explored for their possible impact on care for certain types of non-small cell lung cancer.